Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.

Kiadis sheds half its staff as lead cell therapy bombs

Janssen/AbbVie drug approved in graft-versus-host disease

First use for Imbruvica outside blood cancer.

Imbruvica granted fourth Breakthrough status

The drug is also granted Orphan Drug Designation by the FDA.